Mainz Registry of Flow-mediated Constriction
|Coronary Artery Disease|
|Study Type:||Observational [Patient Registry]|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Target Follow-Up Duration:||2 Years|
|Official Title:||Mainz Registry of Flow-mediated Constriction|
- Endothelial function [ Time Frame: Baseline ]Flow-mediated constriction (change in diameter of the radial artery induced by a reduction in local shear stress) will be measured at entry in the registry
- Endothelial function [ Time Frame: Baseline ]Flow-mediated dilation (change in diameter of the radial artery in response to increases in shear stress) will be measured at entry in the registry
Biospecimen Retention: Samples Without DNA
|Study Start Date:||September 2009|
|Estimated Study Completion Date:||April 2018|
|Estimated Primary Completion Date:||April 2018 (Final data collection date for primary outcome measure)|
Patients undergoing coronary angiography
Consecutive patients referred for coronary angiography for the suspect of coronary artery disease
Coronary artery disease (CAD) is a lifelong process resulting from the interaction of many risk factors, environmental influences, and genetic predisposition. Although the collection of medical history and standard risk factors provides essential information, the existence of complex interactions among different risk factors, risk modifications by medical therapy, and inter-individual differences complicate these issues. In the light of these limitations, alternative approaches have been sought, and the non-invasive assessment of endothelial function has been proposed as a possible non-invasive and inexpensive endpoint that could reflect the cumulative cardiovascular burden and/or the responsiveness to therapies at the level of individual patients.
A total of 1000 consecutive patients undergoing elective coronary angiography will be studied. Patients have chest pain on effort according to the American College of Cardiology/American Heart Association 2007 Guidelines and/or a pathological exercise or dobutamine stress test. Patients undergoing catheterization for any reason other than stable (suspected) CAD (e.g. for hypertensive crisis associated with troponin elevation, or acute coronary syndromes, valvular heart disease, congenital heart disease, cardiomyopathy, etc.) will be excluded. Patients with known chronic inflammatory diseases, dialysis, or decompensated/severe heart failure will be also excluded.
Blood samples will be drawn from all patients after a fasting period of at least 12 h and will be examined with the use of routine laboratory methods for blood counts, lipid parameters, C-reactive protein, renal and hepatic function. Coronary risk factors were defined as: obesity (body mass index >30 kg/m2); age; smoking (or previous smoking); hyperlipidaemia (total serum cholesterol >220 mg/dL and/or serum triglycerides >200 mg/dL); hypertension (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg on two consecutive seated measurements or therapy with antihypertensive medication); family history (first-degree relatives with cardiovascular disease); diabetes mellitus (fasting serum glucose levels >126 mg/dL or therapy with oral hypoglycaemic agents or insulin).
The methods employed for L-FMC/FMD (flow mediated dilation)'analysis in our laboratory have been previously published (Gori Journal of the American College of Cardiology 2008). Briefly, patients will be placed supine, the left arm immobilized, and L-FMC and FMD will be measured using a Vivid 7 (General Electrics, Munich, Germany) ultrasound platform equipped with a 14 MHz matrix probe and a micrometric probe holder. Low-flow-mediated constriction corresponds to the constriction observed during a 4.5 min occlusion of a pneumatic cuff placed distal to the site of arterial diameter measurement. Flow-mediated dilation corresponds to the maximal dilation observed in the 5 min following deflation of the cuff, i.e. during reactive hyperaemia. Repeatability and reproducibility data of these methods have been recently reported (intra-class correlation coefficient=0.68 and 0.80 for FMD and L-FMC, respectively).
All data will be acquired digitally and analysed in a randomized, blinded fashion prior to coronary angiography by an investigator not aware of the clinical status of the patient, using automatic dedicated software.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01787370
|Contact: Tommaso Gori, MD PhD||+49 6131 firstname.lastname@example.org|
|University Medical Center Mainz||Recruiting|
|Mainz, Rheinland Pfalz, Germany, 55131|
|Contact: Tommaso Gori, MD PhD +496131172829 email@example.com|
|Principal Investigator:||Tommaso Gori, MD PhD||Universitätsmedizin Mainz|